RTNXF - Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
2024-05-15 18:15:29 ET
Renalytix Plc (RNLX)
Q3 2024 Results Conference Call
May 15, 2024 08:30 AM ET
Company Participants
Peter DeNardo - CapComm Partners
James McCullough - Chief Executive Officer
James Sterling - Chief Financial Officer
Howard Doran - Chief Business Officer
Conference Call Participants
Dan Arias - Stifel
Randy Baron - Pinnacle Associates
Mark Massaro - BTIG
Jens Lindqvist - Investec
Presentation
Operator
Good morning, and welcome to the Renalytix conference call to review Third Quarter Fiscal Year 2024 Financial Results. [Operator Instructions]. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Peter DeNardo of Capcomm Partners for a few introductory comments.
Peter DeNardo
Thank you, Olivia. Thank you all for participating in today's call. Joining me today from Renalytix to provide formal remarks are James McCullough, Chief Executive Officer; and James Sterling, Chief Financial Officer; and Howard Doran, President, on hand for our question-and-answer session.
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Examples of these statements include without limitation, the potential benefits, including economic savings of KidneyIntelX, the commercial prospects of KidneyIntelX, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketing our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail cost of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes, trends in our market and potential benefits of government policy change, the impact of COVID-19 and other world events on our business.
Our expectations regarding product development, strategic partnerships and collaborations, reimbursement decisions, clinical studies and regulatory submissions, our business strategies and future growth, including plans, expectations and opportunities for financing operations and revenue projections and guidance.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our annual report on Form 10-K that was filed on September 28, 2023, with the Securities and Exchange Commission....
Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript